BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-279@pharmaconomics
DTSTAMP:20260707T035950Z
DTSTART;VALUE=DATE:20260505
DTEND;VALUE=DATE:20260506
SUMMARY:CYTK Phase 3 — aficamten
DESCRIPTION:Phase 3 trial results for aficamten in non-obstructive hypertrophic cardiomyopathy are due May 5\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1061983/000119312526067012/cytk-ex99_1.htm\n\nTrack it: https://www.pharmaconomics.com/e/279
URL:https://www.pharmaconomics.com/e/279
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:CYTK catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR